<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03963141</url>
  </required_header>
  <id_info>
    <org_study_id>D2287R00139</org_study_id>
    <nct_id>NCT03963141</nct_id>
  </id_info>
  <brief_title>Retrospective Analysis to Describe Patient Profiles, Current Treatment Patterns and Economic Burden for Asthma Patients in UAE. A Descriptive Analysis of the Asthma Patient Population in the Emirate of Dubai With Respect to Healthcare Resource Utilization, Costs, and Asthma-related Treatment Pattern</brief_title>
  <official_title>Retrospective Analysis to Describe Patient Profiles, Current Treatment Patterns and Economic Burden for Asthma Patients in UAE.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Retrospective cohort study with an overall objective of to perform a descriptive
      analysis of the asthma patient population in the Emirate of Dubai with respect to healthcare
      resource utilization, costs, and asthma-related treatment patterns and outcome.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 7, 2019</start_date>
  <completion_date type="Anticipated">August 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Asthma Patients Number</measure>
    <time_frame>1 Year</time_frame>
    <description>Number of unique asthma patients in the database during December 2015 through November 2018(summarized annually).it will be computed in the follow-up period and will be reported as a percentage and number of visits per person per year (PPPY). Utilization will be considered &quot;all-cause&quot; if the associated medical claim(s) has a diagnosis code in any position for any condition.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Asthma-related Cost</measure>
    <time_frame>1 Year</time_frame>
    <description>Total asthma-related cost reported in the databse during December 2015 through November 2018(summarized annually).It will will be computed in the follow-up period and will be reported as a percentage and number of visits per person per year (PPPY). Utilization will be considered &quot;asthma-related&quot; if the associated medical claim(s) has ICD-10 diagnosis code for asthma as the principal diagnosis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Asthma-related hopitalizations cost</measure>
    <time_frame>1 Year</time_frame>
    <description>Number of asthma related hopistalizations and cost reported in the database during December 2015 through Novemebr 2018(Summairzed annually)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Astma-related prescription pattern</measure>
    <time_frame>1 Year</time_frame>
    <description>Prescription pattern of asthma-related medication by drug class during December 2015 through November 2018</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of Asthma per total number of patients</measure>
    <time_frame>1 Year</time_frame>
    <description>Number of patients classified as Mild, moderate and severe asthmatic patinets as per the international guidlines.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">12000</enrollment>
  <condition>Asthma</condition>
  <eligibility>
    <study_pop>
      <textblock>
        All patients with a diagnosis of asthma during the identification period will be considered
        for the analysis
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Minimum two claims with asthma diagnosis, 30 days apart, during the identification
             period

          -  Minimum 12 months of baseline period

          -  Age ≥ 18 years on the index date

          -  Continuous enrolment during the baseline period and at least 180 days of follow-up
             period; enrolment will be defined based on at least one activity during each 90-day
             period from the index date

        Exclusion Criteria:

        • Diagnosis of COPD during the baseline period. Diagnosis of COPD will be defined as ≥1
        medical claim with an ICD-10 diagnosis in any position
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>AstraZeneca Clinical Study Information Center</last_name>
    <phone>1-877-240-9479</phone>
    <email>information.center@astrazeneca.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dha Claim</name>
      <address>
        <city>Dubai</city>
        <country>United Arab Emirates</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United Arab Emirates</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 3, 2019</study_first_submitted>
  <study_first_submitted_qc>May 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2019</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

